“The challenges to global public health from unscrupulous producers are as clear as the solutions are elusive,” said Rabin Martin Senior Partner Dr. Jeffrey L. Sturchio in an article published in the June 16–22 edition of The Economic Times magazine. Written by journalist Ullekh NP, the piece highlighted the problem of fake and substandard medications in India and China. The counterfeit drug business is an estimated $50 billion to $200 billion global industry that poses a significant threat to health.
Jeff is a global health thought leader with deep expertise on the issue of counterfeit medications. Last month, he delivered an address at the opening of the Center for Pharmaceutical Advancement and Training, which was launched by the U.S. Pharmacopeial Convention (USP) to increase the number of resources to combat substandard and counterfeit medicines in Sub-Saharan Africa.
Categories: counterfeit medications